[go: up one dir, main page]

WO2010077101A3 - 신규한 티아졸리딘디온 유도체 및 그의 용도 - Google Patents

신규한 티아졸리딘디온 유도체 및 그의 용도 Download PDF

Info

Publication number
WO2010077101A3
WO2010077101A3 PCT/KR2009/007995 KR2009007995W WO2010077101A3 WO 2010077101 A3 WO2010077101 A3 WO 2010077101A3 KR 2009007995 W KR2009007995 W KR 2009007995W WO 2010077101 A3 WO2010077101 A3 WO 2010077101A3
Authority
WO
WIPO (PCT)
Prior art keywords
thiazolidinedione derivative
novel thiazolidinedione
chemical formula
following chemical
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/007995
Other languages
English (en)
French (fr)
Other versions
WO2010077101A2 (ko
WO2010077101A4 (ko
Inventor
조훈
무영
최철희
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chosun University Industry Academic Cooperation Foundation
Original Assignee
Chosun University Industry Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42310414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010077101(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chosun University Industry Academic Cooperation Foundation filed Critical Chosun University Industry Academic Cooperation Foundation
Priority to EP09836422.7A priority Critical patent/EP2383263B1/en
Priority to US13/142,924 priority patent/US8637558B2/en
Priority to KR1020117017782A priority patent/KR101172638B1/ko
Publication of WO2010077101A2 publication Critical patent/WO2010077101A2/ko
Publication of WO2010077101A3 publication Critical patent/WO2010077101A3/ko
Publication of WO2010077101A4 publication Critical patent/WO2010077101A4/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 하기 화학식 1로 표시되는 신규 화합물 및 그의 용도에 관한 것이다. 보다 구체적으로 본 발명은 하기 화학식 1로 표시되는 신규한 티아졸리딘디온 유도체 및 이를 포함하는 약학적 조성물에 관한 것이다. 본 발명에 따른 하기 화학식 1의 신규한 티아졸리딘디온 유도체는 프로스타글란딘을 분해하는 15-하이드록시프로스타글란딘 탈수소화효소(15-PGDH)를 억제하는 활성을 나타내므로 심혈관계질환, 위장질환 및 신장질환을 예방 또는 치료하는데 효과적으로 사용될 수 있고, 탈모의 예방 및 발모 촉진에 효과적으로 사용될 수 있을 뿐만 아니라 골형성 촉진 및 화상 치료에도 효과적으로 사용할 수 있다.
PCT/KR2009/007995 2008-12-30 2009-12-30 신규한 티아졸리딘디온 유도체 및 그의 용도 Ceased WO2010077101A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP09836422.7A EP2383263B1 (en) 2008-12-30 2009-12-30 Novel thiazolidinedione derivative and use thereof
US13/142,924 US8637558B2 (en) 2008-12-30 2009-12-30 Thiazolidinedione derivative and use thereof
KR1020117017782A KR101172638B1 (ko) 2008-12-30 2009-12-30 신규한 티아졸리딘디온 유도체 및 그의 용도

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2008-0136921 2008-12-30
KR20080136921 2008-12-30
KR20090055326 2009-06-22
KR10-2009-0055326 2009-06-22

Publications (3)

Publication Number Publication Date
WO2010077101A2 WO2010077101A2 (ko) 2010-07-08
WO2010077101A3 true WO2010077101A3 (ko) 2010-10-21
WO2010077101A4 WO2010077101A4 (ko) 2011-01-13

Family

ID=42310414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/007995 Ceased WO2010077101A2 (ko) 2008-12-30 2009-12-30 신규한 티아졸리딘디온 유도체 및 그의 용도

Country Status (4)

Country Link
US (1) US8637558B2 (ko)
EP (1) EP2383263B1 (ko)
KR (1) KR101172638B1 (ko)
WO (1) WO2010077101A2 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3295940A1 (en) 2012-04-16 2018-03-21 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
US9261497B2 (en) 2012-10-16 2016-02-16 New York University Method of treating cancer with modulators of SCFSkp2
US9789116B2 (en) 2013-10-15 2017-10-17 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CN107921025A (zh) 2015-03-08 2018-04-17 卡斯西部储备大学 用于治疗纤维症的短链脱氢酶活性的抑制剂
JP2018511616A (ja) * 2015-04-14 2018-04-26 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
KR20180038460A (ko) * 2015-07-21 2018-04-16 이뮤노젠 아이엔씨 세포독성 벤조다이아제핀 유도체의 제조 방법
WO2017074043A1 (ko) * 2015-10-27 2017-05-04 주식회사 이에이치엘바이오 15-pgdh 억제제를 처리한 세포 또는 그것의 배양물을 포함하는 조성물과 그의 용도
KR101843927B1 (ko) * 2015-10-27 2018-03-30 주식회사 이에이치엘바이오 15-pgdh 억제제를 처리한 세포 또는 그것의 배양물을 포함하는 조성물과 그의 용도
KR101817287B1 (ko) 2016-01-08 2018-01-10 조선대학교 산학협력단 티아졸리딘디온 유도체 및 그의 용도
EP3439667B1 (en) * 2016-04-05 2024-01-03 Immune Sensor, LLC Cgas antagonist compounds
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
CA3059255A1 (en) * 2017-04-07 2018-10-11 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
KR101912142B1 (ko) * 2018-01-04 2018-10-29 주식회사 이에이치엘바이오 15-pgdh 억제제를 처리한 세포 또는 그것의 배양물을 포함하는 조성물과 그의 용도
EA202191422A1 (ru) 2018-11-21 2021-10-21 Кейс Вестерн Ризерв Юниверсити Композиции и способы модулирования активности короткоцепочечной дегидрогеназы

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018746A1 (en) * 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders
WO2004093803A2 (en) * 2003-04-16 2004-11-04 Pintex Pharmaceuticals, Inc. Photochemotherapeutic compounds for use in treatment of pin1-associated states
US20070065472A1 (en) * 2005-06-28 2007-03-22 L'oreal Benzyl-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss of keratin fibers
US20070071699A1 (en) * 2005-06-28 2007-03-29 L'oreal Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening
WO2008109727A1 (en) * 2007-03-07 2008-09-12 Janssen Pharmaceutica N.V. Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US5807895A (en) 1994-11-29 1998-09-15 Schwarz Pharma, Inc. Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
WO1996018400A1 (en) * 1994-12-13 1996-06-20 Euro-Celtique, S.A. Trisubstituted thioxanthines
ID23971A (id) 1997-09-09 2000-06-14 Procter & Gamble Prostaglandin tetrahidro tersubstitusic c<16>-c<20> aromatik yang berguna sebagai agonis fp
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
KR100850133B1 (ko) 2004-01-05 2008-08-04 니콕스 에스. 에이. 프로스타글란딘 나이트로옥시 유도체
FR2887443A1 (fr) * 2005-06-28 2006-12-29 Oreal Utilisation de composes benzylidene-1,3-thiazolidine-2,4- diones pour favoriser et/ou induire et/ou stimuler la pigmentation des matieres keratiniques et/ou limiter leur depigmentation et/ou leur blanchement.
US20070059265A1 (en) * 2005-06-28 2007-03-15 L'oreal Benzylidene-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss and/or for increasing the density of keratin fibers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018746A1 (en) * 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders
WO2004093803A2 (en) * 2003-04-16 2004-11-04 Pintex Pharmaceuticals, Inc. Photochemotherapeutic compounds for use in treatment of pin1-associated states
US20070065472A1 (en) * 2005-06-28 2007-03-22 L'oreal Benzyl-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss of keratin fibers
US20070071699A1 (en) * 2005-06-28 2007-03-29 L'oreal Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening
WO2008109727A1 (en) * 2007-03-07 2008-09-12 Janssen Pharmaceutica N.V. Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2383263A4 *

Also Published As

Publication number Publication date
WO2010077101A2 (ko) 2010-07-08
EP2383263A2 (en) 2011-11-02
US20110269954A1 (en) 2011-11-03
KR20110107358A (ko) 2011-09-30
EP2383263B1 (en) 2014-04-16
EP2383263A4 (en) 2012-08-22
KR101172638B1 (ko) 2012-08-08
WO2010077101A4 (ko) 2011-01-13
US8637558B2 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
WO2010077101A3 (ko) 신규한 티아졸리딘디온 유도체 및 그의 용도
WO2010057101A3 (en) Compounds useful as hiv blockers
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2009153496A3 (fr) Composes agonistes ppar, preparation et utilisations pour le traitement du diabete et/ou des dyslipidemies
WO2008006547A3 (en) Pyrrolopyrimidines for pharmaceutical compositions
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2008067119A3 (en) Novel compounds
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2009016410A3 (en) Chemical compounds 831
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2006099943A8 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
WO2011039735A3 (en) Compounds with ddx3 inhibitory activity and uses thereof
WO2010066629A3 (en) Novel azaindoles
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
WO2011047055A8 (en) Novel mek inhibitors, useful in the treatment of diseases
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
WO2008131946A3 (de) Substituierte amid-derivate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09836422

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13142924

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2009836422

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117017782

Country of ref document: KR

Kind code of ref document: A